---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-26-000034"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:46:50.926683+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul

## Summary
- Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.
- Mojdeh Poul departed as President and CEO and from the Board effective April 30, 2026; she receives $566,526 lump sum.
- Essig receives $1,075,000 base salary, 125% target bonus, and initial equity awards totaling $8 million in RSUs and options.
- Michael McBreen appointed Chief Commercial Officer with base salary $660,000 and $1,000,000 one-time equity award.
- Essig previously served as Integra's CEO from 1997 to 2012 and as Executive Chairman from February 2024 to June 2025.

## SEC filing metadata
- accession: 0000917520-26-000034
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/0000917520-26-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/iart-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-26-000034
- JSON: https://secwatch.observer/filing/0000917520-26-000034.json
- Plain text: https://secwatch.observer/filing/0000917520-26-000034.txt

## Key facts
- Executive change
  Stuart M. Essig was appointed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/0000917520-26-000034-index.htm
- Executive change
  Mojdeh Poul departed as Director at INTEGRA LIFESCIENCES HOLDINGS CORP.
  - Action: departed
  - Role: Director
  source text: Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/0000917520-26-000034-index.htm
- Executive change
  Mojdeh Poul departed as President and Chief Executive Officer at INTEGRA LIFESCIENCES HOLDINGS CORP.
  - Action: departed
  - Role: President and Chief Executive Officer
  source text: Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752026000034/0000917520-26-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.